Sophia Genetics backs FY24 revenue view $65M-$67M, consensus $65.66M

Backs FY24 adjusted gross margin view 72%-72.5%. Camblong added, “Looking ahead, I’m excited by major growth catalysts such as our new Liquid Biopsy application MSK ACCESS(R) powered with SOPHiA DDMTM, which has already attracted an impressive 18 new customers since its launch in Q2. I am also excited by the recent launch of the application’s Solid Tumor testing counterpart, MSK-IMPACT(R) powered with SOPHiA DDMTM. These applications, which enable any institution across the globe to launch best-in-class Liquid Biopsy and Solid Tumor testing, are also igniting strong interest from BioPharma companies who can leverage the decentralized, global network to improve deployment and development of their therapies.”